BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development

The panel, which featured the acting directors of Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, and the acting chief of staff, focused on the FDA’s current priorities and initiatives.

The post BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development appeared first on GEN - Genetic Engineering and Biotechnology News.